Eli Lilly To Present New Data Across Its Cardiometabolic Health Portfolio At The Annual Meeting of the European Association for the Study of Diabetes; Results From TRIUMPH-2 Showed Investigational Triple Hormone Receptor Agonist Retatrutide Delivered Substantial Weight Loss And A1C Improvements In Obesity And Type 2 Diabetes
Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide), Mounjaro (tirzepatide) and Foundayo (orforglipron), will present new data across its cardiometabolic health portfolio at the 62nd Annual Meeting of
Eli Lilly showed that a new medicine helped people lose weight and control blood sugar. When a company presents good study results, it can signal progress on products people need.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.